Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.

Pharmgenomics Pers Med · 2013 · PMC3792616 · PMID 24109193

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

17 Of note, a Phase III trial testing topotecan treatment versus PLD treatment showed a trend toward a higher RR in the platinum-resistant OC patient subset treated with PLD, although there was no improvement of PFS or OS. 18 , 19 Gemcitabine Gemcitabine could be considered an alternative to PLD for treatment of platinum-resistant OC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.